The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Jun 2020 07:00

RNS Number : 6484P
Midatech Pharma PLC
11 June 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Midatech Pharma Plc

 

Oddfellows House

19 Newport Road

Cardiff CF24 0AA

United Kingdom

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Acacia Research Corporation

City and country of registered office (if applicable)

Irvine, California, United States of America

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

10/06/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.91%

9.91%

39,252,557

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares of £0.001 each

GB00BKT14T00

3,891,284

9.91%

SUBTOTAL 8. A

3,891,284

9.91%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Acacia Research

Corporation

9.91%

9.91%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

New York, New York, USA

Date of completion

09/06/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFBMITMTBBMAM
Date   Source Headline
10th Mar 20169:00 amRNSNotice of Audited Full Year Results
29th Feb 20167:00 amRNSMidatech Celebrates Rare Disease Day
23rd Feb 20168:59 amRNSHolding(s) in Company
6th Jan 20167:00 amRNSPre-close Trading Update
4th Jan 20167:00 amRNSLicencing agreement signed with Emergex Vaccines
30th Dec 20157:00 amRNSClosing of product acquisition
23rd Dec 20157:00 amRNSIssue of Equity
18th Dec 20151:09 pmRNSDirector/PDMR Shareholding
18th Dec 20157:00 amRNSMidatech agrees to acquire Zuplenz®,
14th Dec 20157:00 amRNSAgreement with Centurion Pharma
9th Dec 20157:10 amRNSMidatech Appoints RBC as Joint Broker
7th Dec 20157:00 amRNSClosing of acquisition
3rd Dec 20152:34 pmRNSMerger Update: Amount of New Shares to be Issued
3rd Dec 20157:00 amRNSMerger Update: Acquisition of DARA BioSciences
19th Nov 20159:30 amRNSSupplemental Disclosure
25th Sep 20157:00 amRNSIssue of equity from exercise of share options
14th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20159:10 amRNSMidatech to Present at Rodman & Renshaw Conference
2nd Sep 20157:00 amRNSNotice of Interim Results
13th Aug 20157:00 amRNSOcular Agreement with Ophthotech
12th Aug 20157:00 amRNSFiling of Form F-4 Registration Statement with SEC
23rd Jul 20157:00 amRNSInitiation of Phase IIa study of insulin delivery
26th Jun 201512:38 pmRNSDirector's Share Purchase
25th Jun 20153:03 pmRNSMidatech Pharma-Posting of Annual Financial Report
24th Jun 20157:00 amRNSDirector/PDMR Shareholding
23rd Jun 20153:43 pmRNSDirector/PDMR Shareholding
4th Jun 20157:00 amRNSProposed Acquisition of DARA BioSciences, Inc.
26th May 20152:05 pmRNSResult of AGM
26th May 20157:01 amRNSAnnual General Meeting
24th Apr 20154:12 pmRNSIssue of equity from exercise of share options
22nd Apr 20159:41 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Apr 20157:04 amRNSPreliminary Results
14th Apr 20157:00 amRNSResearch Collaboration Signed
1st Apr 20157:00 amRNSMidatech Pharma - Board Change
31st Mar 20151:42 pmRNSChange of Registered Office Address
26th Mar 20157:00 amRNSNotice of Maiden Preliminary Results
23rd Mar 201510:43 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Mar 20157:00 amRNSResearch Collaboration Signed with Global Pharma
24th Feb 20157:00 amRNSTrading Update
19th Feb 20157:00 amRNSPositive Results in Proof-of-Concept Study
2nd Jan 20158:30 amRNSHolding(s) in Company
17th Dec 20147:00 amRNSAward of EU grant funding
9th Dec 20143:37 pmRNSHolding(s) in Company
8th Dec 201412:00 pmRNSMidatech Pharma acquires Q Chip

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.